Drug Trial Radar · NCT03146416
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jun 25, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
May 16, 2017
Primary completion
Jun 14, 2018
Study completion Jun 14, 2018
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- May 10, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to compare the safety and tolerability of subcutaneous (SC) and intravenous (IV) doses of evinacumab in healthy Japanese and Caucasian subjects.
Conditions
- Healthy Volunteers
Interventions
EvinacumabDrug
SC or IV administration of Evinacumab
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline up to week 31
- Severity of TEAEsTime frame: Baseline up to week 31
Locations
1 site in 1 country. Site status is shown where the registry gives one.
WCCT Global, Inc.
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.